American Heart Journal
Volume 151, Issue 5 , Pages 975.e1-975.e9 , May 2006

Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II

  • Christie M. Ballantyne, MD

      Affiliations

    • Methodist DeBakey Heart Center and Baylor College of Medicine, Houston, TX
    • Corresponding Author InformationReprint requests: Christie M. Ballantyne, MD, Department of Medicine, Baylor College of Medicine, 6565 Fannin, M.S. A-601, Houston, TX 77030.
    • ,
  • Marcelo Bertolami, MD

      Affiliations

    • Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil
    • ,
  • Hugo Ricardo Hernandez Garcia, MD

      Affiliations

    • Centro Medico Nacional de Occidente IMSS, Guadalajara, Mexico
    • ,
  • Daniel Nul, MD

      Affiliations

    • Instituto Medico Constituyentes, Buenos Aires, Argentina
    • ,
  • Evan A. Stein, MD

      Affiliations

    • MRL International, Highland Heights, KY
    • ,
  • Pierre Theroux, MD

      Affiliations

    • Montreal Heart Institute, Montreal, Quebec, Canada
    • ,
  • Robert Weiss, MD

      Affiliations

    • Androscoggin Cardiology Associates, Auburn, MI
    • ,
  • Valerie A. Cain, MS

      Affiliations

    • AstraZeneca, Wilmington, DE
    • ,
  • Joel S. Raichlen, MD

      Affiliations

    • AstraZeneca, Wilmington, DE

Received 12 September 2005 ,Accepted 14 December 2005.

References 

  1. National Cholesterol Education Program Adult Treatment Panel III . Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–3421
  2. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–239
  3. Grundy SM. Low-density lipoprotein, non–high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation. 2002;106:2526–2529
  4. Pearson TA, Laroura I, Chu H, et al. The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160:459–467
  5. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol. 2003;92:152–160
  6. Steiner P, Freidel J, Bremmer W, et al. Standardization of micromethods for plasma cholesterol, triglyceride and HDL-cholesterol with the clinics' methodology [abstract]. J Clin Chem Biochem. 1981;19:850–851
  7. Miller RG. Simultaneous statistical inference. 2nd ed.. New York (NY): Springer; 1981;
  8. Sueta CA, Chowdhury M, Boccuzzi SJ, et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1999;83:1303–1307
  9. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice . Executive summary. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2003;24:1601–1610
  10. Genest J, Frolich J, Foder G, et al. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ. 2003;169:921–924
  11. IMS National Prescription Audit, April 2004-March 2005.
  12. Schneck DW, Knopp RH, Ballantyne CM, et al. Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am J Cardiol. 2003;91:33–41
  13. Schuster H, Barter PJ, Stender S, et al. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. Am Heart J. 2004;147:705–712
  14. Olsson AG, Istad H, Luurila O, et al. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J. 2002;144:1044–1051
  15. Shepherd J, Hunninghake DB, Stein EA, et al. Safety of rosuvastatin. Am J Cardiol. 2004;94:882–888
  16. Barter P, Taylor R, Ditmarsch M, et al. Measuring effective reductions in cholesterol using rosuvastatin therapy (MERCURY I): safety analysis from an open-label extension. Atheroscler. 2005;6:101;Abstract W16-P-005

PII: S0002-8703(06)00016-0

doi: 10.1016/j.ahj.2005.12.013

American Heart Journal
Volume 151, Issue 5 , Pages 975.e1-975.e9 , May 2006

Article Tools

* Image Usage & Resolution